{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:20:54Z","timestamp":1793852454351,"version":"4.6.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 1 portion of SENTRY\/XPORT-MF-034 (NCT04562389) evaluated the exportin 1 inhibitor selinexor (40 mg\/60 mg once weekly) plus ruxolitinib in JAK inhibitor\u2013na\u00efve patients with myelofibrosis (n = 24). Primary end points were maximum tolerated selinexor dose, recommended clinical trial dose, and safety. No dose-limiting toxicities were reported. Common adverse events were nausea, fatigue, anemia, thrombocytopenia, constipation, vomiting, and headache. Nausea was transient, mainly grade 1, and managed by prophylactic antiemetics. Four deaths occurred, all unrelated to study treatment. Selinexor 60 mg in combination with ruxolitinib was identified as the recommended phase 3 dose based on safety, efficacy, and exposure\u2013response analyses. Overall safety profiles and grades of clinically significant adverse events were similar and generally manageable regardless of selinexor dose. A greater proportion of patients achieved spleen volume reduction of \u226535% (SVR35) and total symptom score reduction of \u226550% (TSS50) at week 24 in the selinexor 60-mg group (79% and 58%) than the 40-mg group (38% and 25%). Among evaluable patients who received suboptimal ruxolitinib \u22645 mg twice daily in the selinexor 60-mg group, SVR35 was observed in 100% (6\/6) and TSS50 in 75% (3\/4) of patients. The trial was registered at ClinicalTrials.gov as NCT04562389.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018706","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:58:56Z","timestamp":1772737136000},"page":"3383-3397","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Selinexor plus ruxolitinib in JAK inhibitor\u2013na\u00efve patients with myelofibrosis: a multicenter, open-label, phase 1 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"first","affiliation":[{"name":"1Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mohan","sequence":"additional","affiliation":[{"name":"2Vanderbilt Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[{"name":"2Vanderbilt Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-2940","authenticated-orcid":false,"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Maher","sequence":"additional","affiliation":[{"name":"4VCU Massey Comprehensive Cancer Center, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-587X","authenticated-orcid":false,"given":"Yi","family":"Chai","sequence":"additional","affiliation":[{"name":"5Karyopharm Therapeutics, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Gudi","sequence":"additional","affiliation":[{"name":"5Karyopharm Therapeutics, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Taverna","sequence":"additional","affiliation":[{"name":"5Karyopharm Therapeutics, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Mark","sequence":"additional","affiliation":[{"name":"5Karyopharm Therapeutics, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas K.","family":"Tantravahi","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"5","key":"2026052610374569500_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026052610374569500_bib2","first-page":"456","article-title":"JAK inhibitors in the treatment of myelofibrosis","volume":"20","author":"Levavi","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2026052610374569500_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2026052610374569500_bib4","author":"United States Food and Drug Administration","year":"2021"},{"key":"2026052610374569500_bib5","author":"United States Food and Drug Administration","year":"2021"},{"key":"2026052610374569500_bib6","author":"United States Food and Drug Administration","year":"2022"},{"key":"2026052610374569500_bib7","author":"United States Food and Drug Administration","year":"2023"},{"issue":"8","key":"2026052610374569500_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2026052610374569500_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12185-016-2050-y","article-title":"Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis","volume":"104","author":"Song","year":"2016","journal-title":"Int J Hematol"},{"issue":"9","key":"2026052610374569500_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2026052610374569500_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oncolo\/oyab058","article-title":"Treatment patterns, health care resource utilization, and cost in patients with myelofibrosis in the United States","volume":"27","author":"Copher","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"2026052610374569500_bib12","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"2026052610374569500_bib13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026052610374569500_bib14","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/S2352-3026(22)00140-5","article-title":"Making a case for disease-modifying agents in myelofibrosis","volume":"9","author":"Maffioli","year":"2022","journal-title":"Lancet Haematol"},{"issue":"13","key":"2026052610374569500_bib15","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"suppl 1","key":"2026052610374569500_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study [abstract]","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052610374569500_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2023-173509","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis [abstract]","volume":"142","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"48","key":"2026052610374569500_bib18","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"2026052610374569500_bib19","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026052610374569500_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"39","key":"2026052610374569500_bib21","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","article-title":"Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death","volume":"9","author":"Argueta","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"2026052610374569500_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026052610374569500_bib23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-015-1936-z","article-title":"KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models","volume":"15","author":"Gravina","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"2026052610374569500_bib24","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.18632\/oncotarget.13485","article-title":"Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma","volume":"8","author":"Garg","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2026052610374569500_bib25","doi-asserted-by":"crossref","first-page":"F1179","DOI":"10.1152\/ajprenal.00406.2014","article-title":"Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels","volume":"307","author":"Tan","year":"2014","journal-title":"Am J Physiol Ren Physiol"},{"issue":"7","key":"2026052610374569500_bib26","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","article-title":"Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026052610374569500_bib27","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2023-186674","article-title":"Use of combination therapies including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients","volume":"142","author":"Lu","year":"2023","journal-title":"Blood"},{"key":"2026052610374569500_bib28","author":"Maloof","year":"3  2023"},{"issue":"9","key":"2026052610374569500_bib29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2026052610374569500_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"2026052610374569500_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk Res"},{"issue":"12","key":"2026052610374569500_bib32","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"2026052610374569500_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2010.01.005","article-title":"Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study","volume":"34","author":"Teman","year":"2010","journal-title":"Leuk Res"},{"issue":"9","key":"2026052610374569500_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/PAI.0000000000000000","article-title":"Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis","volume":"22","author":"Sangle","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2026052610374569500_bib35","unstructured":"Center for Drug Evaluation and Research\n          . Application Number: 202192Orig1s000 \u2013 Clinical Pharmacology and Biopharmaceutis Review(s). 2011. Accessed 9 July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202192Orig1s000ClinPharmR.pdf."},{"key":"2026052610374569500_bib36","doi-asserted-by":"crossref","first-page":"1649493","DOI":"10.3389\/fonc.2025.1649493","article-title":"Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy","volume":"15","author":"Baljevic","year":"2025","journal-title":"Front Oncol"},{"issue":"7","key":"2026052610374569500_bib37","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from International Myeloma Foundation Expert Roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2026052610374569500_bib38","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1016\/j.clml.2021.07.014","article-title":"Optimal supportive care with selinexor improves outcomes in patients with relapsed\/refractory multiple myeloma","volume":"21","author":"Chari","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026052610374569500_bib39","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2026052610374569500_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14796694.2025.2461393","article-title":"Selinexor plus ruxolitinib in JAK inhibitor treatment-na\u00efve myelofibrosis: SENTRY phase 3 study design","volume":"21","author":"Mascarenhas","year":"2025","journal-title":"Future Oncol"},{"issue":"6","key":"2026052610374569500_bib41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cam4.136","article-title":"Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review","volume":"2","author":"Mitra","year":"2013","journal-title":"Cancer Med"},{"issue":"6","key":"2026052610374569500_bib42","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026052610374569500_bib43","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"33","key":"2026052610374569500_bib44","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026052610374569500_bib45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ajh.24098","article-title":"Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls","volume":"90","author":"Anderson","year":"2015","journal-title":"Am J Hematol"},{"issue":"18","key":"2026052610374569500_bib46","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"Passamonti","year":"2022","journal-title":"Future Oncol"},{"issue":"5","key":"2026052610374569500_bib47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.16729","article-title":"Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis","volume":"191","author":"Barraco","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2026052610374569500_bib48","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1002\/cam4.5618","article-title":"Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: an Italian MYNERVA Project","volume":"12","author":"Coltro","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"2026052610374569500_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-018-0642-0","article-title":"Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study","volume":"11","author":"Talpaz","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026052610374569500_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"suppl 1","key":"2026052610374569500_bib51","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1016\/S2152-2650(24)01451-4","article-title":"Long-term response to selinexor in patients with myelofibrosis and refractory or intolerant to JAK inhibitors: follow-up results of a single-center, phase II, investigator-initiated trial (IIT) [abstract MPN-652]","volume":"24","author":"Tantravahi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026052610374569500_bib52","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2023-181720","article-title":"A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in patients with JAK inhibitor-na\u00efve myelofibrosis and moderate thrombocytopenia (XPORT-MF-044) [abstract]","volume":"142","author":"Scandura","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026052610374569500_bib53","doi-asserted-by":"crossref","first-page":"12248","DOI":"10.1038\/s41598-018-30686-1","article-title":"Anti-tumor efficacy of selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor","volume":"8","author":"Subhash","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"2026052610374569500_bib54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026052610374569500_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jha2.854","article-title":"Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis","volume":"5","author":"Oh","year":"2024","journal-title":"EJHaem"},{"issue":"suppl 1","key":"2026052610374569500_bib56","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S2152-2650(24)01443-5","article-title":"MPN-527 selinexor and ruxolitinib impact on symptom burden in patients with myelofibrosis is potentially driven by inhibition of NF-\u03baB and activation of P53 pathways","volume":"24","author":"Tantravahi","year":"2024","journal-title":"Clin Lymphoma Myeloma"},{"issue":"9","key":"2026052610374569500_bib57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2026052610374569500_bib58","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"24","key":"2026052610374569500_bib59","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1002\/cncr.35489","article-title":"Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: the RUX-MF Real-World Study","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"key":"2026052610374569500_bib60","first-page":"848473","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","volume":"2015","author":"Davis","year":"2015","journal-title":"Adv Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3383\/2518728\/blooda_adv-2025-018706-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3383\/2518728\/blooda_adv-2025-018706-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:58Z","timestamp":1779806278000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3383\/566937\/Selinexor-plus-ruxolitinib-in-JAK-inhibitor-naive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018706","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,13]]}}}